首页 > 最新文献

International Journal of Angiology最新文献

英文 中文
Biomarkers for Postoperative Intimal Hyperplasia. 术后内膜增生的生物标志物。
IF 0.5 Q4 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-02-25 eCollection Date: 2025-06-01 DOI: 10.1055/a-2524-1844
Mitsuhiro Yamamura, Taichi Sakaguchi, Hiroe Tanaka, Ken-Ichi Watanabe, Hisashi Uemura, Yuji Sakashita, Yoshio Teshima, Masashi Bungo

Interleukin-8 (IL-8) is a neutrophil chemotactic factor produced by vascular endothelial cells. This study aimed to evaluate whether the serum IL-8 level can be the biomarker for postoperative intimal hyperplasia in the rat model. Sixteen male Lewis rats (mean weight: 501 ± 44 g) were subjected in this study. The right epigastric vein graft is interposed into the common femoral artery with 10-0 interrupted sutures, as previously described. Vein grafts from each group were stained with hematoxylin and eosin and Elastica Verhoeff's van Gieson's at 2 and 4 weeks postoperatively. Unoperated right epigastric veins were also examined as a Sham. In Group edaravone, free-radical scavenger, edaravone (Radicut ® , Mitsubishi Tanabe Pharma Corp., Osaka Japan) was administered, instead of saline. The initial areas of vein grafts were measured using computerized planimetry (NIH Image Ver. 1.61). Serum IL-8 levels were measured and compared using an unpaired t -test. This study was approved by the Hyogo College of Medicine Animal Research Committee (No. 235). The average intimal area at 4 weeks in Control group was significantly increased compared with that of Sham group (0.43 ± 0.11 vs. 0.00 ± 0.00 mm 2 , p  < 0.01). The average serum IL-8 levels at 4 weeks were also significantly increased, compared with that of Sham group (148 ± 6 vs. 53 ± 14 pg/mL, p  < 0.05). The serum IL-8 levels in Group edaravone were appeared to be suppressed but not significant (132 ± 24 pg/mL, p  = 0.72). It is very important to detect the biomarker such as the serum IL-8, before the establishment of postoperative intimal hyperplasia.

白细胞介素-8 (IL-8)是一种由血管内皮细胞产生的中性粒细胞趋化因子。本研究旨在评价血清IL-8水平是否可以作为大鼠术后内膜增生的生物标志物。雄性Lewis大鼠16只,平均体重501±44 g。如前所述,将右腹壁静脉移植物插入股总动脉,采用10-0间断缝合线。术后2周和4周,各组静脉移植物分别行苏木精、伊红染色和弹性Verhoeff’s van Gieson’s染色。未手术的右腹壁静脉也被检查为假手术。依达拉奉组为自由基清除剂,使用依达拉奉(Radicut®,Mitsubishi Tanabe Pharma Corp., Osaka Japan)代替生理盐水。采用计算机平面测量法测量静脉移植物的初始面积(NIH Image Ver. 1.61)。测定血清IL-8水平,采用非配对t检验进行比较。本研究已兵库医学院动物研究委员会(No. 235)批准。与Sham组相比,对照组4周时平均内膜面积显著增加(0.43±0.11 vs. 0.00±0.00 mm 2, p p p = 0.72)。在术后内膜增生建立之前,检测血清IL-8等生物标志物是非常重要的。
{"title":"Biomarkers for Postoperative Intimal Hyperplasia.","authors":"Mitsuhiro Yamamura, Taichi Sakaguchi, Hiroe Tanaka, Ken-Ichi Watanabe, Hisashi Uemura, Yuji Sakashita, Yoshio Teshima, Masashi Bungo","doi":"10.1055/a-2524-1844","DOIUrl":"10.1055/a-2524-1844","url":null,"abstract":"<p><p>Interleukin-8 (IL-8) is a neutrophil chemotactic factor produced by vascular endothelial cells. This study aimed to evaluate whether the serum IL-8 level can be the biomarker for postoperative intimal hyperplasia in the rat model. Sixteen male Lewis rats (mean weight: 501 ± 44 g) were subjected in this study. The right epigastric vein graft is interposed into the common femoral artery with 10-0 interrupted sutures, as previously described. Vein grafts from each group were stained with hematoxylin and eosin and Elastica Verhoeff's van Gieson's at 2 and 4 weeks postoperatively. Unoperated right epigastric veins were also examined as a Sham. In Group edaravone, free-radical scavenger, edaravone (Radicut <sup>®</sup> , Mitsubishi Tanabe Pharma Corp., Osaka Japan) was administered, instead of saline. The initial areas of vein grafts were measured using computerized planimetry (NIH Image Ver. 1.61). Serum IL-8 levels were measured and compared using an unpaired <i>t</i> -test. This study was approved by the Hyogo College of Medicine Animal Research Committee (No. 235). The average intimal area at 4 weeks in Control group was significantly increased compared with that of Sham group (0.43 ± 0.11 vs. 0.00 ± 0.00 mm <sup>2</sup> , <i>p</i>  < 0.01). The average serum IL-8 levels at 4 weeks were also significantly increased, compared with that of Sham group (148 ± 6 vs. 53 ± 14 pg/mL, <i>p</i>  < 0.05). The serum IL-8 levels in Group edaravone were appeared to be suppressed but not significant (132 ± 24 pg/mL, <i>p</i>  = 0.72). It is very important to detect the biomarker such as the serum IL-8, before the establishment of postoperative intimal hyperplasia.</p>","PeriodicalId":13798,"journal":{"name":"International Journal of Angiology","volume":"34 2","pages":"164-166"},"PeriodicalIF":0.5,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068914/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144010639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of Left and Right Branch Blocks with Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction. 左、右支阻滞与保留射血分数心衰患者临床结局的关系
IF 0.5 Q4 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-01-31 eCollection Date: 2025-06-01 DOI: 10.1055/a-2516-2082
Sukhila Reddy, Lakshmi Kattamuri, Alok Dwivedi, Debabrata Mukherjee, Abhizith Deoker

The associations of left bundle branch block (LBBB) and right bundle branch block (RBBB) with cardiovascular (CV) outcomes compared with normal QRS in heart failure patients with preserved ejection fraction (HFpEF) are unclear. We sought to determine CV morbidity, mortality, and total costs associated with LBBB and RBBB in acute HFpEF compared with those without BBB. A cross-sectional study using the 2019 NIS database analyzed adult HFpEF hospitalizations for acute heart failure, categorizing patients by LBBB, RBBB, or normal QRS. Clinical outcomes included atrial fibrillation (AF), ventricular fibrillation (VF), complete heart block (CHB), sick sinus syndrome (SSS), cardiac arrest (CA), hospitalization costs, and in-hospital mortality. Associations between BBB types and outcomes were assessed using logistic and relative risk (RR) models with propensity score weighting, validated by sensitivity analyses. A total of 334,511 hospitalizations with HFpEF including LBBB (6,818, 2%) and RBBB (7,948, 2.4%) were analyzed. Compared with normal QRS duration, LBBB was associated with VF (odds ratio [OR] = 2.47, p  < 0.001), SSS (OR = 1.72, p  < 0.001), CHB (OR = 2.77, p  < 0.001) and greater hospitalization costs (RR = 1.15, p  < 0.001) after adjusting for covariates in PS analysis. Similarly, RBBB was associated with AF (OR = 1.30, p  < 0.001), VF (OR = 1.59, p  = 0.033), SSS (OR = 1.72, p  < 0.001), CHB (OR = 2.81, p  < 0.001), CA (OR = 1.19, p  < 0.001), and higher hospitalization costs (RR = 1.08, p  < 0.001). These associations remained unchanged in multiple validation analyses even after additionally adjusting for obesity, hypertension, and diabetes. The length of stay was shorter in HFpEF with RBBB and LBBB subgroups compared with normal QRS. In hospitalizations of acute decompensated HFpEF, BBB was associated with an increased risk of CV outcomes and hospitalization costs.

与正常QRS相比,保留射血分数(HFpEF)的心力衰竭患者左束分支阻滞(LBBB)和右束分支阻滞(RBBB)与心血管(CV)结局的关系尚不清楚。我们试图确定急性HFpEF患者与无血脑屏障患者相比,与LBBB和RBBB相关的CV发病率、死亡率和总成本。一项使用2019年NIS数据库的横断面研究分析了因急性心力衰竭而住院的成人HFpEF,并根据LBBB、RBBB或正常QRS对患者进行了分类。临床结果包括心房颤动(AF)、心室颤动(VF)、完全性心脏传导阻滞(CHB)、病窦综合征(SSS)、心脏骤停(CA)、住院费用和住院死亡率。采用logistic和相对风险(RR)模型(倾向评分加权)评估BBB类型与结局之间的关联,并通过敏感性分析进行验证。共分析了334,511例HFpEF住院病例,包括LBBB(6,818例,2%)和RBBB(7,948例,2.4%)。与正常QRS持续时间相比,LBBB与VF(比值比[OR] = 2.47, p p p p p p = 0.033)、SSS (OR = 1.72, p p p p p)相关
{"title":"Association of Left and Right Branch Blocks with Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction.","authors":"Sukhila Reddy, Lakshmi Kattamuri, Alok Dwivedi, Debabrata Mukherjee, Abhizith Deoker","doi":"10.1055/a-2516-2082","DOIUrl":"10.1055/a-2516-2082","url":null,"abstract":"<p><p>The associations of left bundle branch block (LBBB) and right bundle branch block (RBBB) with cardiovascular (CV) outcomes compared with normal QRS in heart failure patients with preserved ejection fraction (HFpEF) are unclear. We sought to determine CV morbidity, mortality, and total costs associated with LBBB and RBBB in acute HFpEF compared with those without BBB. A cross-sectional study using the 2019 NIS database analyzed adult HFpEF hospitalizations for acute heart failure, categorizing patients by LBBB, RBBB, or normal QRS. Clinical outcomes included atrial fibrillation (AF), ventricular fibrillation (VF), complete heart block (CHB), sick sinus syndrome (SSS), cardiac arrest (CA), hospitalization costs, and in-hospital mortality. Associations between BBB types and outcomes were assessed using logistic and relative risk (RR) models with propensity score weighting, validated by sensitivity analyses. A total of 334,511 hospitalizations with HFpEF including LBBB (6,818, 2%) and RBBB (7,948, 2.4%) were analyzed. Compared with normal QRS duration, LBBB was associated with VF (odds ratio [OR] = 2.47, <i>p</i>  < 0.001), SSS (OR = 1.72, <i>p</i>  < 0.001), CHB (OR = 2.77, <i>p</i>  < 0.001) and greater hospitalization costs (RR = 1.15, <i>p</i>  < 0.001) after adjusting for covariates in PS analysis. Similarly, RBBB was associated with AF (OR = 1.30, <i>p</i>  < 0.001), VF (OR = 1.59, <i>p</i>  = 0.033), SSS (OR = 1.72, <i>p</i>  < 0.001), CHB (OR = 2.81, <i>p</i>  < 0.001), CA (OR = 1.19, <i>p</i>  < 0.001), and higher hospitalization costs (RR = 1.08, <i>p</i>  < 0.001). These associations remained unchanged in multiple validation analyses even after additionally adjusting for obesity, hypertension, and diabetes. The length of stay was shorter in HFpEF with RBBB and LBBB subgroups compared with normal QRS. In hospitalizations of acute decompensated HFpEF, BBB was associated with an increased risk of CV outcomes and hospitalization costs.</p>","PeriodicalId":13798,"journal":{"name":"International Journal of Angiology","volume":"34 2","pages":"92-99"},"PeriodicalIF":0.5,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068908/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144063658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Aorta Rupture Due to Extracorporeal Shock Wave Lithotripsy: A Rare Case Report. 体外冲击波碎石术致主动脉破裂1例。
IF 0.5 Q4 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-01-31 eCollection Date: 2025-06-01 DOI: 10.1055/a-2516-2038
Christos Stagkoglou, Elias Kaperonis, Vasileios Papavasileiou

Since the 1980s, extracorporeal shock wave lithotripsy (ESWL) has been the treatment of choice for most urinary calculi. It is generally considered a safe method with a few complications involving the vascular system, among others. There are only a few literature reports of aortic rupture after ESWL and these mainly concern abdominal aortic aneurysms and rarely, severe atherosclerotic aorta. We report the case of a 67-year-old man with a rupture of a longitudinally and circumferentially calcified abdominal aorta and pseudoaneurysm formation following ESWL which he underwent a few days before the symptoms started. He reported urgently to our department after a recurrence of severe abdominal and lumbar pain. An endovascular treatment attempt with stent graft implantation was made initially but since the perforation did not seal, open surgery with stent removal, hematoma excision, and an aortobifemoral bypass was decided. He died 23 days later because of acute myocardial infarction. We believe that it is possible for severely calcified vessels to rupture through ESWL, and great care should be taken in these patients for symptoms or signs of retroperitoneal hematoma after the procedure.

自20世纪80年代以来,体外冲击波碎石术(ESWL)已成为大多数泌尿系结石的治疗选择。它通常被认为是一种安全的方法,涉及血管系统的并发症很少。只有少数文献报道ESWL后主动脉破裂,这些主要涉及腹主动脉瘤和罕见的严重动脉粥样硬化性主动脉。我们报告的情况下,一个67岁的男子,纵向和圆周钙化的腹主动脉破裂和假性动脉瘤形成后,他接受了ESWL几天前的症状开始。他在严重的腹部和腰部疼痛复发后紧急向我科报告。我们最初尝试血管内支架植入治疗,但由于穿孔没有愈合,我们决定进行开放性手术,取出支架,切除血肿,并行主动脉-股动脉搭桥术。23天后,他死于急性心肌梗塞。我们认为,严重钙化的血管有可能通过ESWL破裂,对于这些患者,应非常小心手术后腹膜后血肿的症状或体征。
{"title":"Aorta Rupture Due to Extracorporeal Shock Wave Lithotripsy: A Rare Case Report.","authors":"Christos Stagkoglou, Elias Kaperonis, Vasileios Papavasileiou","doi":"10.1055/a-2516-2038","DOIUrl":"10.1055/a-2516-2038","url":null,"abstract":"<p><p>Since the 1980s, extracorporeal shock wave lithotripsy (ESWL) has been the treatment of choice for most urinary calculi. It is generally considered a safe method with a few complications involving the vascular system, among others. There are only a few literature reports of aortic rupture after ESWL and these mainly concern abdominal aortic aneurysms and rarely, severe atherosclerotic aorta. We report the case of a 67-year-old man with a rupture of a longitudinally and circumferentially calcified abdominal aorta and pseudoaneurysm formation following ESWL which he underwent a few days before the symptoms started. He reported urgently to our department after a recurrence of severe abdominal and lumbar pain. An endovascular treatment attempt with stent graft implantation was made initially but since the perforation did not seal, open surgery with stent removal, hematoma excision, and an aortobifemoral bypass was decided. He died 23 days later because of acute myocardial infarction. We believe that it is possible for severely calcified vessels to rupture through ESWL, and great care should be taken in these patients for symptoms or signs of retroperitoneal hematoma after the procedure.</p>","PeriodicalId":13798,"journal":{"name":"International Journal of Angiology","volume":"34 2","pages":"159-163"},"PeriodicalIF":0.5,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068923/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143992107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MicroRNA Profiling in Chronic Limb-Threatening Ischemia Their Role in Arteriogenesis. 慢性肢体缺血中的MicroRNA谱及其在动脉发生中的作用。
IF 0.5 Q4 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-01-13 eCollection Date: 2025-06-01 DOI: 10.1055/a-2504-1911
Muhamad T Ismail, Budi Y Setianto, Sofia M Haryana, Dyah W Anggrahini

Chronic limb-threatening ischemia (CLTI) represents poses a substantial threat with escalating mortality and amputation rates. Despite the existence of various clinical techniques for diagnosing CLTI, the role of microRNAs (miRNAs) in arteriogenesis remains ambiguous. Comprehensive knowledge on miRNAs may facilitate the advancement of targeted therapy pertaining to the enhancement of collateral blood flow in obstructed vessels. Therefore, this study aimed at analyzing arteriogenesis-associated plasma miRNA profiles in patients with CLTI using gene expression. Samples were acquired from the collateral arteries (CA group, n  = 3) and the contralateral healthy limb (healthy artery; HA group, n  = 3) of a single set of patients with CLTI. The RNA extracted from the samples was assessed for concentration and purity. A normalization factor was used to address variations in analyte abundance and/or quality across the samples. Subsequently, individual RNA molecules were directly quantified and subjected to comparative analysis between the CA and HA groups to identify the miRNAs involved in arteriogenesis. The five arteriogenesis-related miRNAs exhibiting maximum upregulation were miR-301b-3p, miR-221-5p, miR-639, miR-34a-5p, and let-7a-5p, while the five most downregulated miRNAs included miR-151a-5p, miR-371a-5p, miR-651-5p, miR-510-5p, and miR-660-5p. Summarily, this study documented marked upregulation and downregulation of miRNAs associated with arteriogenesis in the collateral arteries of patients with CLTI as compared with their contralateral healthy limbs. Possible mechanisms involved, including the regulation of YAP/TAZ pathway, TGFBR3 mRNA, SIRT1 expression, and other processes have shown to be modulated by miRNAs fluctuations.

慢性肢体威胁性缺血(CLTI)代表了不断上升的死亡率和截肢率的实质性威胁。尽管存在各种诊断CLTI的临床技术,但microrna (mirna)在动脉发生中的作用仍然不明确。对mirna的全面了解可以促进靶向治疗的发展,从而增强阻塞血管的侧支血流量。因此,本研究旨在通过基因表达分析CLTI患者与动脉形成相关的血浆miRNA谱。从侧支动脉(CA组,n = 3)和对侧健康肢体(健康动脉;HA组,n = 3)为单组CLTI患者。从样品中提取的RNA进行浓度和纯度评估。使用归一化因子来处理样品中分析物丰度和/或质量的变化。随后,对单个RNA分子进行直接量化,并在CA组和HA组之间进行比较分析,以鉴定参与动脉发生的mirna。表现出最大上调的5种与动脉发生相关的mirna是miR-301b-3p、miR-221-5p、miR-639、miR-34a-5p和let-7a-5p,而下调最多的5种mirna包括miR-151a-5p、miR-371a-5p、miR-651-5p、miR-510-5p和miR-660-5p。总之,本研究记录了与对侧健康肢体相比,CLTI患者侧支动脉中与动脉发生相关的mirna显著上调和下调。可能涉及的机制包括YAP/TAZ通路的调控、TGFBR3 mRNA、SIRT1表达等过程均被mirna波动调节。
{"title":"MicroRNA Profiling in Chronic Limb-Threatening Ischemia Their Role in Arteriogenesis.","authors":"Muhamad T Ismail, Budi Y Setianto, Sofia M Haryana, Dyah W Anggrahini","doi":"10.1055/a-2504-1911","DOIUrl":"10.1055/a-2504-1911","url":null,"abstract":"<p><p>Chronic limb-threatening ischemia (CLTI) represents poses a substantial threat with escalating mortality and amputation rates. Despite the existence of various clinical techniques for diagnosing CLTI, the role of microRNAs (miRNAs) in arteriogenesis remains ambiguous. Comprehensive knowledge on miRNAs may facilitate the advancement of targeted therapy pertaining to the enhancement of collateral blood flow in obstructed vessels. Therefore, this study aimed at analyzing arteriogenesis-associated plasma miRNA profiles in patients with CLTI using gene expression. Samples were acquired from the collateral arteries (CA group, <i>n</i>  = 3) and the contralateral healthy limb (healthy artery; HA group, <i>n</i>  = 3) of a single set of patients with CLTI. The RNA extracted from the samples was assessed for concentration and purity. A normalization factor was used to address variations in analyte abundance and/or quality across the samples. Subsequently, individual RNA molecules were directly quantified and subjected to comparative analysis between the CA and HA groups to identify the miRNAs involved in arteriogenesis. The five arteriogenesis-related miRNAs exhibiting maximum upregulation were miR-301b-3p, miR-221-5p, miR-639, miR-34a-5p, and let-7a-5p, while the five most downregulated miRNAs included miR-151a-5p, miR-371a-5p, miR-651-5p, miR-510-5p, and miR-660-5p. Summarily, this study documented marked upregulation and downregulation of miRNAs associated with arteriogenesis in the collateral arteries of patients with CLTI as compared with their contralateral healthy limbs. Possible mechanisms involved, including the regulation of YAP/TAZ pathway, TGFBR3 mRNA, SIRT1 expression, and other processes have shown to be modulated by miRNAs fluctuations.</p>","PeriodicalId":13798,"journal":{"name":"International Journal of Angiology","volume":"34 2","pages":"83-91"},"PeriodicalIF":0.5,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068916/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143968951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnosis and Management of Mitral Valve Disease in the Elderly. 老年二尖瓣疾病的诊断与治疗。
IF 0.9 Q4 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-11-04 eCollection Date: 2025-03-01 DOI: 10.1055/s-0044-1790541
Preetham Kumar, Surya Aedma, Padmini Varadarajan, Ramdas G Pai

Calcific mitral stenosis, commonly seen in the elderly in developed countries, occurs primarily due to mitral annular calcification, and its prevalence is increasing secondary to an aging population. Mitral regurgitation, commonly seen across all age groups, occurs primarily due to anatomical or functional impairment of one or more components of the mitral apparatus or the left ventricle that are necessary for normal valve function, and its prevalence is increasing secondary to an increasing number of patients with heart failure. The current review discusses the diagnosis of and treatment options (medical, surgical, and transcatheter) for mitral valve disease, including the associated challenges, specifically in the elderly.

钙化性二尖瓣狭窄常见于发达国家的老年人,主要是由于二尖瓣环钙化引起的,随着人口老龄化,其患病率也在增加。二尖瓣返流在所有年龄组中都很常见,主要是由于正常瓣膜功能所必需的二尖瓣或左心室的一个或多个部件的解剖或功能损伤,随着心力衰竭患者数量的增加,其患病率也在增加。当前的综述讨论了二尖瓣疾病的诊断和治疗选择(内科、外科和经导管),包括相关的挑战,特别是在老年人中。
{"title":"Diagnosis and Management of Mitral Valve Disease in the Elderly.","authors":"Preetham Kumar, Surya Aedma, Padmini Varadarajan, Ramdas G Pai","doi":"10.1055/s-0044-1790541","DOIUrl":"10.1055/s-0044-1790541","url":null,"abstract":"<p><p>Calcific mitral stenosis, commonly seen in the elderly in developed countries, occurs primarily due to mitral annular calcification, and its prevalence is increasing secondary to an aging population. Mitral regurgitation, commonly seen across all age groups, occurs primarily due to anatomical or functional impairment of one or more components of the mitral apparatus or the left ventricle that are necessary for normal valve function, and its prevalence is increasing secondary to an increasing number of patients with heart failure. The current review discusses the diagnosis of and treatment options (medical, surgical, and transcatheter) for mitral valve disease, including the associated challenges, specifically in the elderly.</p>","PeriodicalId":13798,"journal":{"name":"International Journal of Angiology","volume":"34 1","pages":"10-22"},"PeriodicalIF":0.9,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11813618/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143407438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Snapshot on Clinical Trials on Zotarolimus DES: A Repurposing Drug against Myocardial Infarction. 左他莫司DES:一种抗心肌梗死的再用途药物的临床试验概况。
IF 0.9 Q4 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-10-21 eCollection Date: 2025-03-01 DOI: 10.1055/s-0044-1791556
Vaishali R Undale, Shweta K Lembhe, Shital D Satone, Pratiksha Hase

Myocardial infarction is the permanent death (necrosis) of heart muscle caused by a lack of oxygen for an extended period of time (ischemia). Since the very first percutaneous transluminal coronary angioplasty was done 40 years ago, the science of interventional cardiology has advanced dramatically. The above progression began with a balloon catheter attached to a fixed wire, advancing to bare-metal stents, first-generation drug-eluting stents (DES), second- and third-generation biodegradable polymer-based DES. Ultimately, bioabsorbable stents are still in development. Zotarolimus is a new pharmacologic therapy with a similar reprint address; for example, the antirestenosis agent sirolimus has recently been investigated as part of a stent platform combined with a biomimetic phosphorylcholine and BioLINX polymer for its biological activity, as well as its usefulness as an antiproliferative agent. Several clinical trials have been conducted to assess the safety and efficacy of the zotarolimus drug-eluting stent (Z-DES). Medtronic Medical Devices, a global leader in medical technology (United States), and Abbot Global Health Care and Research began clinical trials on the Z-DES in 2002 and will continue through 2021 (INDIA). Endeavor (E-Zes), Resolute (R-Zes), Resolute Integrity (I-Zes), and Resolute Onyx are the different forms of Z-DES that Medtronic has tested in clinical trials. In comparison to other DES, Z-DES was found to be safe in these clinical trials done across multiple nations and in a diverse demographic. This review helps understand the overall clinical trial of Z-DES.

心肌梗死是由于长时间缺氧(缺血)引起的心肌永久性死亡(坏死)。自从第一例经皮腔内冠状动脉成形术在40年前完成以来,介入心脏病学的科学已经取得了巨大的进步。上述进展从附着在固定金属丝上的球囊导管开始,发展到裸金属支架、第一代药物洗脱支架(DES)、第二代和第三代生物可降解聚合物基DES。最终,生物可吸收支架仍在开发中。佐他莫司是一种新的药物治疗方法,转载地址相似;例如,抗再狭窄药物西罗莫司最近被研究作为支架平台的一部分,与仿生磷胆碱和BioLINX聚合物结合使用,以获得其生物活性,以及作为抗增殖药物的有效性。已经进行了几项临床试验来评估佐他莫司药物洗脱支架(Z-DES)的安全性和有效性。医疗技术领域的全球领导者美敦力医疗器械公司(美国)和Abbot全球医疗保健和研究公司于2002年开始对Z-DES进行临床试验,并将持续到2021年(印度)。Endeavor (E-Zes)、Resolute (R-Zes)、Resolute Integrity (I-Zes)和Resolute Onyx是美敦力在临床试验中测试过的不同形式的Z-DES。与其他DES相比,Z-DES在多个国家和不同人群的临床试验中被发现是安全的。这篇综述有助于了解Z-DES的整体临床试验。
{"title":"A Snapshot on Clinical Trials on Zotarolimus DES: A Repurposing Drug against Myocardial Infarction.","authors":"Vaishali R Undale, Shweta K Lembhe, Shital D Satone, Pratiksha Hase","doi":"10.1055/s-0044-1791556","DOIUrl":"10.1055/s-0044-1791556","url":null,"abstract":"<p><p>Myocardial infarction is the permanent death (necrosis) of heart muscle caused by a lack of oxygen for an extended period of time (ischemia). Since the very first percutaneous transluminal coronary angioplasty was done 40 years ago, the science of interventional cardiology has advanced dramatically. The above progression began with a balloon catheter attached to a fixed wire, advancing to bare-metal stents, first-generation drug-eluting stents (DES), second- and third-generation biodegradable polymer-based DES. Ultimately, bioabsorbable stents are still in development. Zotarolimus is a new pharmacologic therapy with a similar reprint address; for example, the antirestenosis agent sirolimus has recently been investigated as part of a stent platform combined with a biomimetic phosphorylcholine and BioLINX polymer for its biological activity, as well as its usefulness as an antiproliferative agent. Several clinical trials have been conducted to assess the safety and efficacy of the zotarolimus drug-eluting stent (Z-DES). Medtronic Medical Devices, a global leader in medical technology (United States), and Abbot Global Health Care and Research began clinical trials on the Z-DES in 2002 and will continue through 2021 (INDIA). Endeavor (E-Zes), Resolute (R-Zes), Resolute Integrity (I-Zes), and Resolute Onyx are the different forms of Z-DES that Medtronic has tested in clinical trials. In comparison to other DES, Z-DES was found to be safe in these clinical trials done across multiple nations and in a diverse demographic. This review helps understand the overall clinical trial of Z-DES.</p>","PeriodicalId":13798,"journal":{"name":"International Journal of Angiology","volume":"34 1","pages":"23-32"},"PeriodicalIF":0.9,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11813614/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143407347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acute Kidney Injury after Isolated Coronary Bypass Surgery. 孤立冠状动脉搭桥术后急性肾损伤。
IF 0.9 Q4 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-10-07 eCollection Date: 2025-03-01 DOI: 10.1055/s-0044-1791545
John C Slaughter, Daniel L Davenport, Sibu P Saha

Acute kidney injury (AKI) is among the most serious of the common postoperative complications of cardiac surgeries, which can increase the short- and long-term morbidity and mortality of patients. This study aimed to examine possible risk factors that lead to AKI. We sought to compare our AKI rates to national averages in coronary artery bypass grafting (CABG) reported by the Society of Thoracic Surgeons (STS). We reviewed our institution's data for renal failure in CABG procedures performed between January 1, 2020, and June 30, 2023. From the database, we identified 1,068 CABG patients and reviewed demographics, nonmodifiable conditions, and modifiable risk factors. The STS database uses the Risk, Injury, Failure, Loss, and End-stage renal disease definition for renal failure. Of our patient sample, 14 (1.3%) experienced renal failure. The national rate for AKI after isolated CABG was 1.9% in 2023. Chronic lung disease was a risk factor for AKI development. The mean perfusion, cross-clamp, ventilator times, and hospital stay increased in AKI patients. All patients who suffered from AKI had undergone perioperative blood transfusion. Our single-center experience with renal failure is slightly better than the national average. In our population, chronic lung disease and lower preoperative ejection fractions were associated with increased rates of AKI. Modifiable risk factors in our population included perioperative blood transfusion and increased perfusion/cross-clamp times. Lastly, AKI patients spent longer time on ventilators, increased lengths of stay, and increased postoperative mortality.

急性肾损伤(Acute kidney injury, AKI)是心脏手术常见并发症中最严重的一种,可增加患者的短期和长期发病率和死亡率。本研究旨在探讨可能导致AKI的危险因素。我们试图将我们的AKI发生率与胸外科学会(STS)报道的冠状动脉旁路移植术(CABG)的全国平均水平进行比较。我们回顾了本机构在2020年1月1日至2023年6月30日期间进行的CABG手术中肾功能衰竭的数据。从数据库中,我们确定了1068例CABG患者,并回顾了人口统计学、不可改变的条件和可改变的危险因素。STS数据库使用风险、损伤、衰竭、损失和终末期肾脏疾病定义肾衰竭。在我们的患者样本中,14例(1.3%)出现肾衰竭。2023年,全国孤立性冠脉搭桥后AKI发生率为1.9%。慢性肺部疾病是AKI发展的危险因素。AKI患者的平均灌注、交叉钳、呼吸机次数和住院时间均增加。所有AKI患者均接受围手术期输血。我们的单中心治疗肾功能衰竭的经验略好于全国平均水平。在我们的人群中,慢性肺部疾病和较低的术前射血分数与AKI发生率增加相关。我们人群中可改变的危险因素包括围手术期输血和灌注/交叉钳夹次数增加。最后,AKI患者使用呼吸机的时间更长,住院时间延长,术后死亡率增加。
{"title":"Acute Kidney Injury after Isolated Coronary Bypass Surgery.","authors":"John C Slaughter, Daniel L Davenport, Sibu P Saha","doi":"10.1055/s-0044-1791545","DOIUrl":"10.1055/s-0044-1791545","url":null,"abstract":"<p><p>Acute kidney injury (AKI) is among the most serious of the common postoperative complications of cardiac surgeries, which can increase the short- and long-term morbidity and mortality of patients. This study aimed to examine possible risk factors that lead to AKI. We sought to compare our AKI rates to national averages in coronary artery bypass grafting (CABG) reported by the Society of Thoracic Surgeons (STS). We reviewed our institution's data for renal failure in CABG procedures performed between January 1, 2020, and June 30, 2023. From the database, we identified 1,068 CABG patients and reviewed demographics, nonmodifiable conditions, and modifiable risk factors. The STS database uses the Risk, Injury, Failure, Loss, and End-stage renal disease definition for renal failure. Of our patient sample, 14 (1.3%) experienced renal failure. The national rate for AKI after isolated CABG was 1.9% in 2023. Chronic lung disease was a risk factor for AKI development. The mean perfusion, cross-clamp, ventilator times, and hospital stay increased in AKI patients. All patients who suffered from AKI had undergone perioperative blood transfusion. Our single-center experience with renal failure is slightly better than the national average. In our population, chronic lung disease and lower preoperative ejection fractions were associated with increased rates of AKI. Modifiable risk factors in our population included perioperative blood transfusion and increased perfusion/cross-clamp times. Lastly, AKI patients spent longer time on ventilators, increased lengths of stay, and increased postoperative mortality.</p>","PeriodicalId":13798,"journal":{"name":"International Journal of Angiology","volume":"34 1","pages":"51-55"},"PeriodicalIF":0.9,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11813601/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143407430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Jetstream Atherectomy with Paclitaxel-Coated Balloons: 3-Year Outcomes of the Prospective Randomized JET-RANGER Study. 喷射流动脉粥样硬化切除术与紫杉醇涂层气球:前瞻性随机JET-RANGER研究的3年结果。
IF 0.9 Q4 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-10-03 eCollection Date: 2025-03-01 DOI: 10.1055/s-0044-1791546
Nicolas W Shammas, Gail Shammas, Sue Jones-Miller

The JET-RANGER study (NCT03206762) was a multicenter (11 U.S. centers), randomized trial, core-lab adjudicated and designed to demonstrate the superiority of Jetstream + paclitaxel-coated balloon (JET + PCB) versus percutaneous transluminal angioplasty (PTA) + PCB in treating femoropopliteal arterial disease. The 1- and 2-year outcomes have been recently published. The 3-year outcome data are presented in this report. The JET-RANGER trial initially had 47 patients with 48 lesions. Thirty-one in the JET-PCB arm and 16 in the PTA + PCB arm (2:1 randomization). At 3-year follow-ups, there were 20 patients in the JET-PCB arm and 14 patients in the PTA + PCB arm. Kaplan-Meier survival analysis was performed to estimate the freedom from target lesion revascularization (TLR) at 3 years. Bailout stenting was not considered a TLR in this analysis. Statistical significance was determined by a p -value < 0.05. Freedom from TLR was statistically similar between the two groups at 3 years between JET + PCB and PTA + PCB (freedom from TLR was 88.0 vs. 67.8%, respectively, p  = 0.1380). There was also no significant difference in the change of ankle-brachial index (ABI) between the PTA + PCB and JET + PCB from baseline at 6 months ( p  = 0.7890), 1 year ( p  = 0.4070), 2 years ( p  = 0.7410), and 3 years ( p  = 0.8010). There was also no statistical difference between the JET + PCB and PTA + PCB arms for RCC improvement by one or more categories from baseline to 3 years ( p  = 0.8949). There were no minor or major amputations for either arm throughout the 3-year follow-up. Five JET + PCB patients died before the 3-year specified window and none in the PTA + PCB arm ( p  = 0.137). Two of the deaths were due to cancer and three due to cardiac causes. None were deemed related to the device or procedure. JET + PCB had similar freedom from TLR and improvement in ABI and RCC at 3-year follow-up with no difference in amputation or mortality between the 2 arms. A trend toward less TLR was seen in the JET + PCB arm.

JET- ranger研究(NCT03206762)是一项多中心(11个美国中心),随机试验,核心实验室评审,旨在证明Jetstream +紫杉醇涂层球囊(JET + PCB)与经皮腔内血管成形术(PTA) + PCB在治疗股腘动脉疾病方面的优势。最近公布了1年和2年的结果。本报告提供了3年的结果数据。JET-RANGER试验最初有47名患者,48个病变。JET-PCB组31例,PTA + PCB组16例(2:1随机分组)。在3年的随访中,JET-PCB组有20例,PTA + PCB组有14例。Kaplan-Meier生存分析用于估计3年目标病变血运重建(TLR)的自由度。在本分析中,救助支架置入不被认为是TLR。p值p = 0.1380)。与基线相比,PTA + PCB与JET + PCB在6个月(p = 0.7890)、1年(p = 0.4070)、2年(p = 0.7410)和3年(p = 0.8010)时的踝臂指数(ABI)变化也无显著差异。从基线到3年,JET + PCB组和PTA + PCB组在一个或多个类别的RCC改善方面也没有统计学差异(p = 0.8949)。在整个3年的随访中,没有任何手臂发生轻微或严重的截肢。5例JET + PCB患者在3年指定窗口前死亡,而PTA + PCB组无患者死亡(p = 0.137)。其中2人死于癌症,3人死于心脏病。没有一个被认为与器械或手术有关。JET + PCB在3年随访中具有相似的TLR自由度和ABI和RCC的改善,两臂之间的截肢或死亡率没有差异。JET + PCB组有TLR减少的趋势。
{"title":"Jetstream Atherectomy with Paclitaxel-Coated Balloons: 3-Year Outcomes of the Prospective Randomized JET-RANGER Study.","authors":"Nicolas W Shammas, Gail Shammas, Sue Jones-Miller","doi":"10.1055/s-0044-1791546","DOIUrl":"10.1055/s-0044-1791546","url":null,"abstract":"<p><p>The JET-RANGER study (NCT03206762) was a multicenter (11 U.S. centers), randomized trial, core-lab adjudicated and designed to demonstrate the superiority of Jetstream + paclitaxel-coated balloon (JET + PCB) versus percutaneous transluminal angioplasty (PTA) + PCB in treating femoropopliteal arterial disease. The 1- and 2-year outcomes have been recently published. The 3-year outcome data are presented in this report. The JET-RANGER trial initially had 47 patients with 48 lesions. Thirty-one in the JET-PCB arm and 16 in the PTA + PCB arm (2:1 randomization). At 3-year follow-ups, there were 20 patients in the JET-PCB arm and 14 patients in the PTA + PCB arm. Kaplan-Meier survival analysis was performed to estimate the freedom from target lesion revascularization (TLR) at 3 years. Bailout stenting was not considered a TLR in this analysis. Statistical significance was determined by a <i>p</i> -value < 0.05. Freedom from TLR was statistically similar between the two groups at 3 years between JET + PCB and PTA + PCB (freedom from TLR was 88.0 vs. 67.8%, respectively, <i>p</i>  = 0.1380). There was also no significant difference in the change of ankle-brachial index (ABI) between the PTA + PCB and JET + PCB from baseline at 6 months ( <i>p</i>  = 0.7890), 1 year ( <i>p</i>  = 0.4070), 2 years ( <i>p</i>  = 0.7410), and 3 years ( <i>p</i>  = 0.8010). There was also no statistical difference between the JET + PCB and PTA + PCB arms for RCC improvement by one or more categories from baseline to 3 years ( <i>p</i>  = 0.8949). There were no minor or major amputations for either arm throughout the 3-year follow-up. Five JET + PCB patients died before the 3-year specified window and none in the PTA + PCB arm ( <i>p</i>  = 0.137). Two of the deaths were due to cancer and three due to cardiac causes. None were deemed related to the device or procedure. JET + PCB had similar freedom from TLR and improvement in ABI and RCC at 3-year follow-up with no difference in amputation or mortality between the 2 arms. A trend toward less TLR was seen in the JET + PCB arm.</p>","PeriodicalId":13798,"journal":{"name":"International Journal of Angiology","volume":"34 1","pages":"56-59"},"PeriodicalIF":0.9,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11813604/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143407446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preventable Hospital Admission-associated VTE: Thoughts on Thromboprophylaxis as Asians. 可预防的住院相关静脉血栓栓塞:对亚洲人血栓预防的思考。
IF 0.9 Q4 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-10-01 eCollection Date: 2025-03-01 DOI: 10.1055/s-0044-1791544
Esan Saciin D Maran, Chaozer Er, Sandeep Gohar, Thofique Adamjee

Previous studies surveying senior and junior doctors have shown that thromboprophylaxis was not commonly practiced in hospitalized medical patients in three public hospitals in Singapore. We, therefore, conducted an audit of our hospital's venous thromboembolism (VTE) clinic cases to study the proportion of preventable hospital admission-associated VTE (HAAVTE). All newly diagnosed VTE cases referred to our VTE clinic from March 2023 to December 2023 were reviewed, to identify those potentially associated with recent hospital admissions. We then reviewed the medical records of those cases to see if thromboprophylaxis was prescribed if indicated. HAAVTEs that had high VTE risk and did not receive appropriate thromboprophylaxis (pharmacological or mechanical) were considered preventable HAAVTE. Thirteen cases of HAAVTEs were identified, out of which only one was given the appropriate thromboprophylaxis. The proportion of preventable HAAVTE was 92.3%. Thromboprophylaxis is not widely practiced in our hospital. More effort is required to improve local thromboprophylaxis practice for hospitalized patients to reduce the burden of preventable HAAVTE.

先前调查高级和初级医生的研究表明,在新加坡的三家公立医院,血栓预防在住院患者中并不常见。因此,我们对我院的静脉血栓栓塞(VTE)临床病例进行了审计,以研究可预防的住院相关VTE (HAAVTE)的比例。我们回顾了2023年3月至2023年12月期间所有新诊断的静脉血栓栓塞病例,以确定那些可能与近期住院有关的病例。然后我们回顾了这些病例的医疗记录,看看是否有血栓预防处方。静脉血栓栓塞风险高且未接受适当血栓预防(药物或机械)的HAAVTE被认为是可预防的HAAVTE。13例HAAVTEs被确定,其中只有一个给予适当的血栓预防。可预防的HAAVTE比例为92.3%。血栓预防在我们医院没有广泛实施。需要更多的努力来改善住院患者的当地血栓预防实践,以减轻可预防的HAAVTE的负担。
{"title":"Preventable Hospital Admission-associated VTE: Thoughts on Thromboprophylaxis as Asians.","authors":"Esan Saciin D Maran, Chaozer Er, Sandeep Gohar, Thofique Adamjee","doi":"10.1055/s-0044-1791544","DOIUrl":"10.1055/s-0044-1791544","url":null,"abstract":"<p><p>Previous studies surveying senior and junior doctors have shown that thromboprophylaxis was not commonly practiced in hospitalized medical patients in three public hospitals in Singapore. We, therefore, conducted an audit of our hospital's venous thromboembolism (VTE) clinic cases to study the proportion of preventable hospital admission-associated VTE (HAAVTE). All newly diagnosed VTE cases referred to our VTE clinic from March 2023 to December 2023 were reviewed, to identify those potentially associated with recent hospital admissions. We then reviewed the medical records of those cases to see if thromboprophylaxis was prescribed if indicated. HAAVTEs that had high VTE risk and did not receive appropriate thromboprophylaxis (pharmacological or mechanical) were considered preventable HAAVTE. Thirteen cases of HAAVTEs were identified, out of which only one was given the appropriate thromboprophylaxis. The proportion of preventable HAAVTE was 92.3%. Thromboprophylaxis is not widely practiced in our hospital. More effort is required to improve local thromboprophylaxis practice for hospitalized patients to reduce the burden of preventable HAAVTE.</p>","PeriodicalId":13798,"journal":{"name":"International Journal of Angiology","volume":"34 1","pages":"78-81"},"PeriodicalIF":0.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11813597/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143407451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comment on Clinical Presentation and Risk Stratification of Pulmonary Embolism. 肺栓塞的临床表现及危险分层。
IF 0.9 Q4 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-10-01 eCollection Date: 2025-06-01 DOI: 10.1055/s-0044-1791547
Hugh A Glazier, Amir Kaki
{"title":"Comment on Clinical Presentation and Risk Stratification of Pulmonary Embolism.","authors":"Hugh A Glazier, Amir Kaki","doi":"10.1055/s-0044-1791547","DOIUrl":"10.1055/s-0044-1791547","url":null,"abstract":"","PeriodicalId":13798,"journal":{"name":"International Journal of Angiology","volume":"34 2","pages":"167"},"PeriodicalIF":0.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068919/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144018812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
International Journal of Angiology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1